Ivan Milanov

TL;DR: Comparing epidemiological indices among European countries is a hard task and often leads only to approximate estimates, which represents a major methodological concern when evaluating the MS burden in Europe and when implementing specific cost‐of‐illness studies.

TL;DR: A dysfunction in systems subserving DNICs in both migraine and CTTH is demonstrated, demonstrating that impairment of endogenous supraspinal pain modulation systems may contribute to the development and/or maintenance of central sensitization in primary headaches.

TL;DR: A multicentre, double-blind, randomised, placebo-controlled, dose-response study to evaluate the safety, efficacy, and tolerability of adjunctive cenobamate in patients with uncontrolled focal (partial)-onset epilepsy.

TL;DR: The RIII reflex threshold (Tr) and the threshold of pain sensation (Tp) were significantly reduced on the symptomatic side in patients with episodic CH during the bout, which may suggest a role for secondary central sensitization in pain pathways.

TL;DR: The primary efficacy outcome was the dose-response effect on the composite of incident MRI-detected covert brain infarcts and recurrent symptomatic ischaemic stroke at or before 26 weeks after randomisation, and the safety outcome was major or clinically relevant non-major bleeding.